Pregled bibliografske jedinice broj: 539718
Look: High throughput in personalized medicine for European citizens.
Look: High throughput in personalized medicine for European citizens. // 57. Plenary Meeting of the European Medical Research Council, European Science Foundation.
Strasbourg, Francuska, 2010. (pozvano predavanje, međunarodna recenzija, sažetak, ostalo)
CROSBI ID: 539718 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Look: High throughput in personalized medicine for European citizens.
Autori
Pavelić, Krešimir
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Skup
57. Plenary Meeting of the European Medical Research Council, European Science Foundation.
Mjesto i datum
Strasbourg, Francuska, 13.10.2010. - 14.10.2010
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Personalized medicine; forward look; high-throughput
Sažetak
An important goal in personalized medicine involves identifying the traits that a cell actually exhibits in terms of quantifiable alterations in the expression of molecules such as proteins, different RNA forms, carbohydrates, lipids and other metabolites. While two people might have identical gene sequences at a particular point on their genome, the way that their individual DNA is packaged into chromatin at that point can have a profound effect on the activation of that gene and as a consequence its involvement in a pathophysiological pathway that leads to disease. Personalized medicine is medicinal model emphasizing the systematic use of information about an individual patient to select or optimize that patient's preventative and therapeutic care. Personalized medicine can broadly be defined as products and services that leverage the science of genomics and proteomics (directly or indirectly) and capitalize on the trends toward wellness and consumerism to enable tailored approaches to prevention and care. In order to facilitate the implementation of personalised medicine into healthcare and thereby fully benefit at the societal level from the potential significant contributions made by this novel area to modern medicine, integration needs to be well prepared and based on thorough strategic analysis. The challenges ahead are significant, and it is becoming clear that regulatory systems operate in a far more complex ways than we might have previously thought. Nevertheless, these technologies could lead to innovative therapies, limit adverse effects of treatments, increase the quality of clinical care, create an optimal fit between a patient and a treatment, and decrease the costs of healthcare. Healthcare is on the brink of a revolution by dramatic advances in biomedical research.The medicine of the future will be personalized and preventive which could result in better health and more cost-effective healthcare for Europeans. In conclusion, personalized medicine is generating innovative treatments and therapies, limiting adverse events, increasing the quality of clinical care, creating a more optimal patient-treatment-fit, and decreasing health care costs.
Izvorni jezik
Engleski
POVEZANOST RADA
Projekti:
335-0982464-2393 - Molekularna obilježja miofibroblasta Dupuytrenove bolesti (Pavelić, Krešimir, MZOS ) ( CroRIS)
Ustanove:
Sveučilište u Rijeci - Odjel za biotehnologiju
Profili:
Krešimir Pavelić
(autor)